Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00158951 · ClinicalTrials.gov registry record · Phase 2
Device Evaluation of Contak Renewal 2and Easytrak 2 - DECREASE-HF
A Phase 2 study of Congestive Heart Failure, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
- 1
- Study location
NCT00158951 is a Phase 2 study of Congestive Heart Failure that has completed, run by Boston Scientific Corporation. The registered enrollment target is 360 participants, above the 323-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (11% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00158951, a Phase 2 study of Congestive Heart Failure, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical investigation is to demonstrate the safety and effectiveness of the CONTAK® RENEWAL™ 2/4/4HE cardiac resynchronization therapy defibrillator (CRT-D) family and EASYTRAK® 2 lead in delivering LV-CRT or BiV-CRT with an LV Offset for patients with heart failure and an indication for an ICD.
Conditions Studied
Interventions
- DEVICE CONTAK RENEWAL 2/4/4HE CRT-D
- DEVICE EASYTRAK 2 Lead
Study Locations (1)
Minnesota
- Multiple Locations in the US - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2003-03 |
| Est. Completion | 2004-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00158951
The ClinicalTrials.gov registry entry for NCT00158951 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 323-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (11% higher). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congestive Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which CONTAK RENEWAL 2/4/4HE CRT-D is the first listed.
NCT00158951 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00158951 about?
NCT00158951 is a clinical study titled "Device Evaluation of Contak Renewal 2and Easytrak 2 - DECREASE-HF". The purpose of this clinical investigation is to demonstrate the safety and effectiveness of the CONTAK® RENEWAL™ 2/4/4HE cardiac resynchronization therapy defibrillator (CRT-D) family and EASYTRAK® 2 lead in delivering LV-CRT or BiV-CRT with an LV Offset for patients with heart failure and an indic...
What is the current status of trial NCT00158951?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2003-03. Estimated completion is 2004-10.
What conditions does trial NCT00158951 study?
This clinical trial studies the following conditions: Congestive Heart Failure.
What interventions are being tested in trial NCT00158951?
The interventions under investigation include: CONTAK RENEWAL 2/4/4HE CRT-D (DEVICE), EASYTRAK 2 Lead (DEVICE).
Who is sponsoring clinical trial NCT00158951?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00158951 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congestive Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
ACTIVE NOT RECRUITING · Phase 2
-
At-Home Automated External Defibrillator (AED) Training Study
COMPLETED · Phase 2
-
Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes
COMPLETED · Phase 2
-
Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.
COMPLETED · Phase 2
-
Palliative Care for People With HF
RECRUITING
-
Circulating Markers for Ischemic Heart Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.